Open access
Predicting the Long‐Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN‐1 Trial
S. Shinde
Florian Kahles
S. Vasileva-Metodiev
R. Griffin
H. Liu-Seifert
Jérémie Lebrec
Neena A. Xavier
Run-Jia Li
S. Klise
Ambrish Singh
Jens Aberle
Sep 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11452 - 11462 · 0 citations
· 25 references
Medicine
Abstract
To assess change in long‐term predicted 10‐year cardiometabolic risk (Type 2 diabetes [T2D] and cardiovascular disease [CVD]) in adults with overweight or obesity without T2D.